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esponsibility of Xi’Abstract
A novel bioanalytical method was developed and validated for the quantitative determination of darunavir
(DRV) in rat plasma by employing hydrophilic interaction chromatography and tandem mass spectro-
metry (HILIC–MS/MS) with supported liquid extraction (SLE). Irbesartan (IRB) was used as an internal
standard (IS). The analyte in rat plasma (200 mL) was isolated through SLE using ethyl acetate as the
eluting solvent. The chromatographic separation was achieved on Luna-HILIC (250 mm 4.6 mm, 5 μm)
column with a mobile phase of 0.1% of formic acid in water:acetonitrile (5: 95, v/v), at a constant ﬂow
rate of 1.0 mL/min. The MS/MS ion transitions for DRV (548.1-392.0) and IS (429.2-207.1) were
monitored on an ion trap mass spectrometer, operating in the multiple reaction monitoring (MRM) mode.
The lower limit of quantitation (LLOQ) was 0.2 ng/mL and quantitation range was 0.2–5000 ng/mL. The
method was validated for its selectivity, sensitivity, carryover, linearity, precision, accuracy, recovery,
matrix effect and stability. The method was successfully applied to pharmacokinetic study in rats.
& 2014 Xi’an Jiaotong University. Production and hosting by Elsevier B.V. All rights reserved.1. Introduction
Hydrophilic interaction chromatography (HILIC) has been
gaining importance and utilization since this concept was ﬁrst
introduced by Alpert in 1990 [1]. HILIC is complimentary tosity. Production and hosting by Elsev
1
160123x1733.
(P.S. Devi).
an Jiaotong University.reverse phase liquid chromatography and provides good
retention and unique selectivity for polar compounds. It has
been proven to be a valuable technique for analyzing polar
drugs and metabolites in biological matrices. The highly
volatile organic mobile phase used in HILIC can provide
increased sensitivity with ESI-MS. In addition, the organic
extracts from protein precipitation (PPT), liquid–liquid extrac-
tion (LLE) or solid phase extraction (SPE) are compatible with
the higher organic content in HILIC mobile phases and can oftenier B.V. All rights reserved.
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elimination of the time-consuming evaporation and reconstitution
steps during preparation of biological samples. In bioanalysis, mostly,
liquid samples including whole blood, plasma, serum, urine or saliva
are handled. Thus an appropriate sample preparation technique should
be properly chosen according to the needs of the developed method.
Such methods should facilitate a sample preparation step keeping the
main focus on decrease of sample amount and solvent consumption,
shortening sample preparation time, reducing the number of steps,
minimizing analysis cost and enabling automation. PPT, LLE and
SPE are among the most commonly used sample cleanup techniques
for biological sample analysis. However, supported liquid extraction
(SLE) is a newly developed sample cleanup technology which is
particularly suitable for the 96-well format operation. Similar to the
traditional LLE, SLE provides very clean extracts with a high
recovery and such bioanalytical LC–MS/MS or GC–MS assays have
been developed and validated using SLE packed with diatomaceous
earth material [10–18]. Also several methods have been published to
quantify darunavir (DRV) in different biological matrices alone [19–
22], and in combination [23–33] with many other protease inhibitors,
nucleoside and non-nucleoside reverse transcriptase inhibitors (NRTI
and NNRTI), integrase inhibitor, raltegravir and an entry inhibitor,
maraviroc. The above methods require solvent evaporation and
reconstitution steps prior to sample injection, while the present
method facilitates direct injection. To the best of our knowledge,
there has been no published HILIC–MS/MS method for the analysis
of DRV alone in rat plasma using SLE. The aim of the present work
was to demonstrate the application of a combination of SLE with
direct injection of the organic extract into a HILIC–MS/MS system,
for the simple and rapid analysis of DRV in rat plasma adopting SLE
for sample preparation. The SLE extract can be injected directly onto
the HILIC column, eliminating the need for lengthy evaporation and
reconstitution steps, and increasing higher throughput. The retention
times of DRV and the internal standard (IS) were low enough (3.3
and 4.5 min), allowing a short run time of 5.0 min. These improve-
ments helped to develop a rapid, simple and sensitive SLE-HILIC–
MS/MS method for the determination of DRV in rat plasma and thus
the method was successfully applied to a pharmacokinetic study.2. Experimental
2.1. Chemicals and materials
Reference standard of DRV (purity, 99.4%) and irbesartan (IRB)
(purity, 99.8%) were procured from Hetero Drugs Limited (Hyderabad,
India). HPLC grade methanol, acetonitrile, methyl tert-butyl ether,
diethyl ether, ethyl acetate, dichloro methane, iso-propyl alcohol and
formic acid were obtained from Merck Specialties Pvt. Ltd. (Mumbai,
India). Water used in the entire analysis was prepared from Milli-Q
water puriﬁcation system procured from Millipore (Bangalore, India).
Freshly obtained drug free rat plasma was collected from male Wistar
rats in our laboratory and stored at 80 1C prior to use.
2.2. LC–MS/MS analysis
Chromatographic separation was accomplished by HILIC using the
isocratic mode of elution. Chromatography was performed on Luna-
HILIC (250 mm 4.6 mm, 5 μm) column. LC–MS/MS studies were
performed using an Agilent 1100 MSD ion-trap-SL mass spectro-
meter with ESI source in positive-ion mode equipped with a degasser
(G1379A), binary pump (G1312A), autosampler (G1329A),autosampler thermostat (G1329B) and diode array detector
(G1315B). All the systems were procured from Agilent Technologies
(Waldbronn, Germany). The data were acquired and processed using
Chemstation 5.3 (Bruker, Waldbronn, Germany). An isocratic elution
with 0.1% formic acid in water:acetonitrile (5:95, v/v) as mobile phase
was pumped at a ﬂow rate of 1.0 mL/min; the sample injection
volume was 20 mL and the column temperature was maintained at
ambient conditions. The sensitivity of the multiple reaction
monitoring (MRM) was optimized by testing with an infusion of
0.1 μg/mL analyte and IS in mobile phase. Detection of the ions
was carried out in the MRM, by monitoring the transition pairs of
m/z 548.1 precursor ions to the m/z 392.2 for DRV and m/z 429.2
precursor ion to the m/z 207.0 product ion for the IS. Nitrogen was
the nebulizer gas. Collision-induced dissociation was achieved
using helium gas as collision gas. The ion source conditions were
set as follows: temperature, 300 1C; nebulizer gas, 35 psi; dry gas,
10.0 L/min; skimmer, 40.0 V; capillary exit, 128.0 V; trap drive,
44.5; maximum accumulation time, 200 ms; Icc target, 30,000.2.3. Preparation of standard solution, calibration standards
and quality control (QC) samples
The standard stock solution of DRV (1000 mg/mL) was prepared by
dissolving requisite amount in methanol. Calibration standards and QC
samples were prepared by spiking blank plasma with stock solution.
Calibration curve standards were made at 0.2 0.5, 1.0, 4.0, 10.0, 50.0,
100, 350, 800, 1500, 3500 and 5000 ng/mL concentrations while QC
samples were prepared at four concentration levels, 4000 ng/mL
(HQC, high quality control), 2500 ng/mL (MQC, medium quality
control), 3.0 ng/mL (LQC, low quality control) and 0.2 ng/mL (LLOQ
QC, lower limit of quantiﬁcation quality control). Stock solution
(500 mg/mL) of the IS was prepared by dissolving 2.5 mg of IS in
5.0 mL of methanol. An aliquot of 20 mL of this solution was further
diluted to 10.0 mL in the same diluent to obtain a solution of 1.0 ng/mL.
All the solutions (standard stock, calibration standards and QC
samples) were stored at 2–8 1C until use.2.4. Sample preparation
SLE extraction was carried out with ﬁve different solvent systems for
the effective extraction of analyte and their compatibility of being
directly injected into HILIC–MS/MS system. Diethyl ether, ethyl
acetate, dichloro methane, iso-propyl alcohol and methyl tert-butyl
ether were found to be compatible for direct injection. A 200 mL
sample aliquot was diluted with 200 mL of water, fortiﬁed with 50 mL
of 1 ng/mL IS working solution and loaded onto an isolute SLEþ
cartridge. After the analyte was allowed to equilibrate with the sorbent
for a minimum of 5 min, it was eluted with 1 mL extraction solvent but
the process was hastened by applying a little pressure from the top with
a rubber bulb initiating a reasonably faster elution [7,17], and
approximately 20 mL of the solution was injected directly into the
HILIC–MS/MS system for analysis.2.5. Method validation
The validation process was carried out according to Guidance
for Industry-Bioanalytical Method Validation, recommended
by U.S. FDA [34]. The assay was validated for selectivity, sensitivity
(LLOQ), linearity, precision, accuracy, recovery, matrix effect
(ME) and stability.
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The applicability of the developed bioanalytical method (SLE-
HILIC/ESI-MS) for DRV in rat plasma was demonstrated by the
results obtained from pharmacokinetic studies conducted in six
male Wistar rats weighing 180710 g approximately which were
fasted overnight before and 4 h after DRV dosing (The study was
approved of by the Animal Ethical Committee of Indian Institute
of Chemical Technology, Hyderabad). Each rat received an oral
dose of 50 mg/kg of DRV in gum acacia suspension. Blood
samples (0.5 mL) were collected from orbital sinus into EDTA
coated tubes at 0, 0.25, 0.5, 1, 2, 3, 4, 6, 8, 10 and 24 h time
intervals after drug administration. The blood samples were
centrifuged at 5000 rpm for 10 min and the plasma samples were
stored at 80 1C until analysis. The plasma samples were
then analyzed by using the developed SLE-HILIC/ESI-MS
method. Plasma drug concentration–time data were subjected to
noncompartmental pharmacokinetic analysis using linear
trapezoidal rule.Fig. 1 (A) ESI-MS signal at different portions of ACN in mobile
phase and (B) effect of different solvent types on the extraction
efﬁciency.3. Results and discussion
3.1. Mass spectrometry
Mass spectrometric parameters were tuned in both positive and
negative ionization modes for DRV and IS. However, compara-
tively a good response was found in positive ionization mode. The
MS parameters were optimized to maximize the response. Acet-
onitrile offered a higher response than methanol and was therefore
chosen as the organic modiﬁer in the eluent. Prior to analysis
a thorough study was undertaken to arrive at a suitable solvent
system. It was observed that a decrease in polarity enhanced the
chromatographic selectivity and facilitated a greater sensitivity
with respect to mass spectrometric signal intensities (Fig. 1A).
These subtle but distinguishable features were monitored with
various combinations of water:acetonitrile but only water:acetoni-
trile (5:95 v/v) with 0.1% formic acid offered the best of selective
separation and made a huge chromatographic distinction with no
noticeable deterioration of peak shape with a typical run time of
5 min. The amount of formic acid was optimized to obtain a
maximal MS response. Addition of 0.1% formic acid to the mobile
phase was thus found to be an important factor for acquiring the
higher sensitivity. The mass spectra for DRV and IS showed peaks
as protonated molecular ions [MþH]þ at 548.1 and 429.2 m/z,
respectively. The major fragment ions observed in each product
spectrum were at 392.2 m/z and 207.0 m/z for DRV and IS,
respectively (Fig. 2).
3.2. Liquid chromatography
The liquid chromatography was optimized on a HILIC column
under isocratic conditions. Under HILIC conditions, the analyte
interacts with a hydrophilic stationary phase and is eluted with a
high concentration of organic solvent (typically acetonitrile with a
small percentage of water/buffer). The highly organic mobile
phase can result in increased sensitivity with ESI-MS detection. At
the same time, HILIC columns often allows direct injection of
organic extract into the LC–MS/MS system so that the dry-down and
reconstitution steps can be eliminated without compromising the
chromatographic peak shape and quality. Choosing the appropriate
IS is an important aspect to achieve acceptable methodperformance, so different compounds were analyzed to arrive at
a suitable IS but IRB offered high recovery, less analytical run
time and well separated from the analyte under study with better
chromatographic selectivity. Chromatographic separation was
accomplished using isocratic mobile phase system consisting of
0.1% formic acid and acetonitrile (5:95, v/v), and HILIC column
facilitated good peak shape and response even at the lowest
concentration level for both the analyte and IS (Fig. 3). The mobile
phase was operated at a ﬂow rate of 1.0 mL/min. The retention
time of DRV and the IS was low enough (3.3 and 4.5 min),
allowing a short run time of 5.0 min.3.3. Optimization of sample preparation
Traditional LLE is the most commonly used effective extraction
technique across a wide range of applications, but its requirement for
off-line preparation renders the method unsuitable for high-
throughput sample preparation. SLE is a newly developed sample
preparation technique that is similar to the traditional LLE. The
Fig. 2 Product ion mass spectra of (A) DRV (m/z 548.1-392.0, scan range 100–700 amu) and (B) IS (m/z 429.3-207.0, scan range
50–500 amu) in positive ion mode.
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earth. As the analyte under study is in plasma as 1:1 sample/
aqueous solution phase, a selective elution of the analyte alone is
now required. Therefore, a solvent which is immiscible with water
was used for preferential and quantitative elution of analyte alone,
leaving the aqueous portion having plasma behind which is like a
simple partition. In addition to sample preparation, adequate
chromatographic selectivity is an important requirement for valid,
accurate and rugged analytical methods. Herein, a new approach to
analyze DRV by HILIC–ESI-MS/MS is reported. This method
features the direct injection of sample into an HPLC system,
without solvent evaporation and reconstitution steps. In the SLE
experiments, a number of organic solvents as diethyl ether, ethyl
acetate, dichloride methane, iso-propyl alcohol and methyl tert-
butyl ether were used for the elution. The percentage recoveries of
analyte are given in Fig. 1(B). It is evident from Fig. 1(B) that with
dichloro methane, iso-propyl alcohol and methyl tert-butyl ether
the recoveries of DRV and IS were in the range of 45–55% and
40–60%, respectively. Elution with diethyl ether gave reasonable
recoveries of DRV and IS in the range of 68% and 65%
respectively. Among all the solvents studied, ethyl acetate was
found to give cleaner extract and higher recovery (490%) andselected as an optimum solvent for extraction. Here, a combination
of 500, 1000 and 1500 mL eluent and 50, 100 and 200 mL of
plasma was also investigated. We found that when extracting
200 mL plasma and 1000 mL eluent improved the extraction
recovery.3.4. Method validation
Selectivity of the assay method was assessed by evaluating
potential interference or background noise at the LC retention
times for the analyte and IS from endogenous compounds. Six
randomly selected blank plasma samples were tested. However, no
signiﬁcant interfering peak was observed in any of these 6 lots of
blank plasma samples of analyte and IS, indicating that compara-
tively SLE was a cleaner procedure than other extraction methods
[35] (Fig. 4). The linearity of the method was tested by adding
appropriate amount DRV to blank plasma to yield the following
concentrations: 0.2, 0.5, 1.0, 4.0, 10.0, 50.0, 100, 350, 800, 1500,
3500 and 5000 ng/mL, and analyzed in triplicate. The calibration
curve was constructed by plotting the peak area ratios of analyte to
IS vs the nominal concentration in plasma. The data were
Fig. 3 Effects of acetonitrile content in the mobile phase on DRV (100 ng/mL) retention time on the HILIC column.
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showing that the regression equation was y¼0.00012x0.043,
correlation coefﬁcient (r2) was greater than 0.998 for DRV where
‘y’ represents the peak area ratio of analyte to that of IS and ‘x’
represents the concentration of analyte in ng/mL. The intra-day
assay precision and accuracy were obtained by analyzing six
replicates of LLOQ and QC samples on a single day. The inter-day
assay precision and accuracy were obtained by analyzing six
replicates of LLOQ and QC samples on 3 different days. Table 1
shows a summary of intra- and inter-day precision and accuracy
data for LLOQ and QC samples containing DRV. Both intra- and
inter-precision CV (%) values ranged from 0.38% to 8.66%. The
accuracy values were within 95.0–107.6%. These results indicated
that the present method had the acceptable accuracy and precision.
The extraction recovery of each analyte for three levels of QC
samples was assessed by comparing the peak areas of extracted
spiked plasma samples with the peak areas of pure compounds of
the same concentrations in solvent. The recovery of the IS was
evaluated at the concentration used in sample analysis. Matrix
effect was investigated to ensure precision, selectivity and
sensitivity that were not compromised by the matrix screened.
Blank biological samples were extracted and then spiked with the
analyte at three QC levels and IS in six replicates. The correspond-
ing peak areas were compared to those of standard solutions, and
the peak area ratio was deﬁned as the matrix effect. Table 2 shows
the results of the recovery and the matrix effect for DRV and IS.
The results suggested that ion suppression or enhancement from
the plasma matrix was negligible in this study. The carryover was
evaluated by analyzing a blank sample immediately after the
ULOQ (5000 ng/mL) sample of the standard curve. The carryover
level should be o20% of the response observed for the analyte
with respect to LLOQ ando5% of the response observed for the IS atthe working concentration. No signiﬁcant carryover was observed in
the carryover analysis. Stability experiments should reﬂect the condi-
tions likely to be encountered during sample transfer, handling and
analysis. The stability studies were evaluated by measuring the area
response (DRV/IS) of stability samples against freshly prepared
comparison standards at LQC and HQC levels. The stabilities were
examined under different study conditions, i.e., by keeping the samples
at ambient temperature for 5 h (bench-top stability) and storing at
30 1C for 50 days (long-term stability) and the stabilities of DRV in
plasma extracts were also tested by placing samples at ambient
temperature for 24 h (autosampler stability). Freeze/thaw stability was
determined after freezing (30 1C) and thawing for three cycles. All
the stability studies were conducted at LQC and HQC levels using six
replicates at each level. Samples are considered to be stable if assay
values are within the acceptable limits of accuracy (o15% SD) and
precision. The results are summarized in Table 3. The results indicate
that DRV was stable for the entire period of the experiment.3.5. Application
We have succeeded in applying this established SLE-HILIC/ESI-MS
method to study pharmacokinetics of DRV in rats. The mean
plasma concentration versus time proﬁle of DRV is shown in
Fig. 5. The non-compartmental pharmacokinetic parameters of
DRV are summarized in Table 4. The peak plasma concentration
(Cmax 13074 ng/mL) was achieved at 3 h (Tmax). The elimination
half-life (t1/2) of DRV was 5.3170.71 h, while the AUC(0 t) and
AUC(01) were 1014748 ng mL/h and 1064749 ng mL/h respec-
tively. The ratio of mean value of AUC(0 t) to that of AUC(01)
was 95.3%.
Fig. 4 Representative MRM chromatograms of (A) blank rat plasma, (B) rat plasma spiked with 0.2 ng/mL (LLOQ) DRV, 50 ng/mL IS and (C) a
rat plasma sample obtained 1.5 h after an intravenous administration of DRV.
Table 1 Intra- and inter-day precision and accuracy for the detection of DRV in rat plasma.
Analyte Spiked concentration (ng/mL) Intra-day (n¼6) Inter-day (n¼6)
Mean (ng/mL) Accuracy (%) CV (%) Mean (ng/mL) Accuracy (%) CV (%)
DRV 0.2 0.19 95.0 5.27 0.21 105.0 4.71
3.0 3.12 104.0 6.84 3.23 107.6 8.66
2500.0 2543.13 101.7 0.43 2552.05 102.0 0.53
4000.0 4063.08 101.5 0.38 4074.14 101.8 0.59
Table 2 The recovery and matrix effect of DRV and IS (n¼6).
Analyte Concentration (ng/mL) Recovery (%) Matrix effect (%)
Mean7SD RSD (%) Mean7SD RSD (%)
DRV 3 95.2772.52 2.65 94.1372.54 2.68
2500 96.4272.19 2.28 95.5674.01 4.17
4000 94.1671.34 1.42 96.8173.51 3.64
IS 50 92.1371.84 1.99 93.1673.87 4.16
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Table 3 Stability of DRV in rat plasma (n¼6).
Stability tested Concentration added
(ng/mL)
Concentration found
(ng/mL)
Precision
(RSD, %)
Accuracy
(RE, %)
Autosampler stability (at 10 1C for 24 h) 3.0 2.9570.11 3.72 3.33
3000.0 3025.1373.21 1.28 1.25
Bench-top stability (5 h at room temperature) 3.0 3.3570.05 8.47 1.66
3000.0 3013.2473.58 0.88 0.75
Freeze–thaw stability (three cycles) 3.0 3.1870.04 6.34 5.00
3000.0 3020.1772.89 0.71 1.00
Long-term stability (at 70 1C for 50 days) 3.0 2.9870.03 4.68 6.60
3000.0 2994.374.24 1.05 0.75
Fig. 5 Mean plasma concentration–time proﬁle of DRV after an oral
50 mg/kg dose of DRV to male Wistar rats.
Table 4 Pharmacokinetic parameters of DRV after oral
administration at a dose of 50 mg/kg to rats (n¼6).
Pharmacokinetic parameters Mean7SD
Cmax (ng/mL) 13074
Tmax (h) 3.0070.28
t1/2 (h) 5.3170.71
AUC0 t (ng h/mL) 1014748
AUMC0 t (ng h
2/mL) 65187386
AUC01 (ng h/mL) 1064749
AUMC01 (ng h
2/mL) 84087914
MRT01 (h) 7.8970.83
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A high-throughput SLE-HILIC–MS/MS method for the determi-
nation of DRV in rat plasma has been successfully developed and
validated. The SLE is a clean sample preparation technique with
better extraction efﬁciency. The HILIC column allows the direct
injection of the SLE extracts. Thus, the tedious manual steps of
evaporation and reconstitution are eliminated but facilitated an
increased and high throughput recovery. The advantages of the
present approach include avoiding loss of compound during
evaporation and reconstitution due to instability, evaporation, or
adsorption. Furthermore a very low column back pressureproduced under HILIC conditions facilitates increased mobile
phase ﬂow rate to enhance the throughput. The method employed
herein is a simple but novel, rapid and selective analytical option.
SLE extraction with direct injection is an unique value addition to
the present day requirement of higher throughput through cleaner
technologies where an analyte is detected at LLOQ levels of
0.2 ng/mL using 0.2 mL plasma with a calibration range of 0.2–
5000 ng/mL. Thus, the present method ﬁnds a potential utility for
the bioassay of chemical compounds.Acknowledgments
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